RY 169.51 -1.1719% SHOP 175.85 -3.2036% TD 85.4 -0.187% ENB 59.6 -1.715% BN 84.78 -1.4873% TRI 250.65 2.1186% CNQ 43.69 0.9007% CP 110.72 -0.5926% CNR 146.88 0.7891% BMO 142.84 -0.6054% BNS 72.34 -0.0829% CSU 4896.4902 0.1981% CM 87.07 -0.9668% MFC 45.08 6.5217% ATD 71.13 -0.6425% NGT 68.13 0.9932% TRP 64.42 -1.2872% SU 56.73 -0.0176% WCN 266.69 -0.146% L 176.74 -1.5157%
Last update at 2025-02-20T19:02:00Z
CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?
Tue 18 Feb 25, 02:13 PMWhy CRISPR Therapeutics (CRSP) Soared on Friday?
Sat 15 Feb 25, 07:00 AMCrispr Therapeutics price target raised to $86 from $85 at BofA
Wed 12 Feb 25, 03:25 PMCRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
Wed 12 Feb 25, 02:34 PMCRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates
Tue 11 Feb 25, 10:10 PMCRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
Mon 10 Feb 25, 10:50 PMCRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
Fri 07 Feb 25, 02:13 PMCRISPR Therapeutics AG (CRSP): Among Cathie Wood’s Top Stock Picks for 2025
Fri 07 Feb 25, 01:13 AMThe Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex
Thu 06 Feb 25, 10:23 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -650.50000M | 379.53M | -348.05600M | 67.31M | -164.42800M |
| Minority interest | - | - | - | - | - |
| Net income | -650.17500M | 377.66M | -348.86500M | 66.86M | -164.98100M |
| Selling general administrative | 102.46M | 102.80M | 88.21M | 63.49M | 48.29M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | -109.81400M | 913.08M | 0.54M | 289.59M | 3.12M |
| Reconciled depreciation | 24.17M | 17.95M | 9.18M | 4.72M | 3.52M |
| Ebit | -697.33300M | 355.57M | -354.43500M | 42.02M | -162.46200M |
| Ebitda | -673.16100M | 373.53M | -345.25100M | 46.74M | -158.94300M |
| Depreciation and amortization | 24.17M | 17.95M | 9.18M | 4.72M | 3.52M |
| Non operating income net other | 22.66M | 6.00M | 6.38M | 20.57M | -5.48500M |
| Operating income | -673.16100M | 373.53M | -354.43500M | 46.74M | -158.94300M |
| Other operating expenses | 673.60M | 539.55M | 354.98M | 242.85M | 162.07M |
| Interest expense | -46.83300M | 23.96M | 6.38M | 25.29M | 0.00000M |
| Tax provision | -0.32500M | 1.87M | 0.81M | 0.45M | 0.55M |
| Interest income | - | - | - | 5.47M | 4.28M |
| Net interest income | - | - | - | - | 0.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.32500M | 1.87M | 0.81M | 0.45M | 0.55M |
| Total revenue | 0.44M | 913.08M | 0.54M | 289.59M | 3.12M |
| Total operating expenses | 563.35M | 539.55M | 354.98M | 242.85M | 162.07M |
| Cost of revenue | 110.25M | - | - | 179.36M | 113.77M |
| Total other income expense net | 22.66M | 6.00M | 6.38M | 20.57M | -5.48500M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -650.17500M | 377.66M | -348.86500M | 66.86M | -164.98100M |
| Net income applicable to common shares | -650.17500M | 377.66M | -348.86500M | 66.86M | -164.98100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2229.57M | 2243.06M | 2751.88M | 1827.97M | 1066.75M |
| Intangible assets | 0.02M | 0.07M | 0.12M | 0.18M | 0.23M |
| Earning assets | - | - | - | - | - |
| Other current assets | 14.39M | 37.71M | 38.08M | 26.14M | 43.68M |
| Total liab | 346.77M | 367.58M | 352.42M | 163.73M | 127.33M |
| Total stockholder equity | 1882.80M | 1875.48M | 2399.46M | 1664.23M | 939.42M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 50.91M | 65.51M | 91.90M | 71.46M | 41.71M |
| Common stock | 2.50M | 2.44M | 2.39M | 2.28M | 1.85M |
| Capital stock | 2.50M | 2.44M | 2.39M | 2.28M | 1.85M |
| Retained earnings | -999.70000M | -846.09000M | -195.91500M | -573.57600M | -224.71100M |
| Other liab | - | 18.29M | 19.66M | 19.41M | 26.17M |
| Good will | - | - | - | - | - |
| Other assets | - | 16.27M | 22.20M | 18.14M | 6.14M |
| Cash | 389.48M | 211.88M | 923.03M | 1168.62M | 943.77M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 108.79M | 121.11M | 119.88M | 94.26M | 57.11M |
| Current deferred revenue | 4.11M | 12.32M | 1.01M | 2.34M | 0.96M |
| Net debt | -150.84500M | 32.14M | -698.00100M | -1107.19100M | -891.23200M |
| Short term debt | 15.62M | 15.84M | 12.16M | 11.36M | 8.49M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 238.63M | 244.02M | 225.03M | 61.43M | 52.54M |
| Other stockholder equity | 2878.09M | 2734.78M | 2598.05M | 2235.62M | 1162.28M |
| Property plant equipment | - | 163.63M | 137.57M | 42.16M | 72.83M |
| Total current assets | 1908.08M | 1853.03M | 2417.51M | 1716.62M | 987.55M |
| Long term investments | 1.97M | 53.13M | - | - | - |
| Net tangible assets | - | 1875.48M | 2399.46M | 1664.05M | 939.19M |
| Short term investments | 1304.21M | 1603.43M | 1456.10M | 521.71M | - |
| Net receivables | 200.00M | 4.64M | 0.30M | 0.14M | 0.10M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 38.15M | 27.43M | 14.82M | 9.09M | 5.94M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 1.91M | -15.64700M | -5.06700M | -0.08300M | 0.00700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 2.44M | 2.39M | 2.28M | 1.85M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -846.09000M | -195.91500M | -573.57600M | -224.71100M |
| Treasury stock | - | -0.06300M | -0.06300M | -0.06300M | -0.06300M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 13.57M | 16.27M | 22.20M | 18.14M | 6.14M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 321.49M | 390.03M | 334.36M | 111.35M | 79.20M |
| Capital lease obligations | 238.63M | 244.02M | 225.03M | 61.43M | 52.54M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -258.65500M | -953.72500M | -522.81200M | 1.32M | -2.77300M |
| Change to liabilities | 3.64M | 32.21M | 15.24M | 30.01M | 12.36M |
| Total cashflows from investing activities | -258.65500M | -1035.43000M | -541.17000M | 1.32M | -2.77300M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 38.59M | 250.94M | 1016.15M | 430.98M | 315.93M |
| Change to operating activities | 15.39M | -9.71100M | 6.36M | -8.29800M | -3.80200M |
| Net income | -650.17500M | 377.66M | -348.86500M | 66.86M | -164.98100M |
| Change in cash | -715.88400M | -245.52400M | 236.66M | 489.00M | 216.90M |
| Begin period cash flow | 939.94M | 1185.47M | 948.81M | 459.81M | 242.91M |
| End period cash flow | 224.06M | 939.94M | 1185.47M | 948.81M | 459.81M |
| Total cash from operating activities | -495.74100M | 538.97M | -238.36600M | 56.68M | -96.23900M |
| Issuance of capital stock | 0.97M | 213.27M | 982.29M | 415.02M | 307.05M |
| Depreciation | 24.17M | 17.95M | 9.18M | 4.72M | 3.52M |
| Other cashflows from investing activities | - | - | - | 8.01M | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | -37.51400M | -25.74700M | -5.02500M | 332.30M |
| Change to account receivables | 0.30M | -0.16100M | -0.04500M | -0.01100M | 2.54M |
| Sale purchase of stock | 38.59M | 250.94M | 1016.15M | 430.98M | -0.05700M |
| Other cashflows from financing activities | 37.62M | 37.68M | 33.86M | 15.96M | 8.94M |
| Change to netincome | 110.42M | 102.39M | 67.88M | 49.52M | 34.82M |
| Capital expenditures | 37.19M | 81.70M | 18.36M | 6.68M | 2.77M |
| Change receivables | 0.30M | -0.16100M | -0.04500M | -0.01100M | 2.54M |
| Cash flows other operating | 15.90M | -5.18900M | 18.25M | -94.42700M | 15.51M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -715.80400M | -245.51300M | 236.62M | 488.99M | 216.92M |
| Change in working capital | 19.84M | 26.86M | 33.44M | -48.43000M | 10.55M |
| Stock based compensation | 97.95M | 102.39M | 66.02M | 44.06M | 34.98M |
| Other non cash items | 12.47M | 14.11M | 1.86M | -10.53300M | 15.41M |
| Free cash flow | -532.92900M | 457.27M | -256.72400M | 49.99M | -99.01200M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CRSP Crispr Therapeutics AG |
-2.755 5.20% | 50.27 | - | 23.36 | 17.06 | 1.78 | 8.76 | 14.16 |
| NVO Novo Nordisk A/S |
0.31 0.37% | 83.71 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.01 1.22% | 83.81 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
7.45 1.58% | 479.21 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
11.20 1.63% | 696.86 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Baarerstrasse 14, Zug, Switzerland, 6300
| Name | Title | Year Born |
|---|---|---|
| Dr. Samarth Kulkarni Ph.D. | CEO & Director | 1979 |
| Mr. Brendan Smith M.B.A. | Sr. VP, CFO & Principal Accounting Officer | 1976 |
| Dr. Lawrence Otto Klein Ph.D. | Chief Operating Officer | 1982 |
| Mr. James R. Kasinger | Gen. Counsel & Sec. | 1972 |
| Dr. Rodger Novak M.D. | Founder, Chairman & Pres | 1967 |
| Mr. Shaun Foy | Founder | NA |
| Dr. Emmanuelle Marie Charpentier | Co-Founder & Scientific Advisory Board Member | NA |
| Dr. Craig C. Mello Ph.D. | Scientific Founder & Advisory Board Member | NA |
| Dr. Chad A. Cowan Ph.D. | Scientific Founder | NA |
| Dr. Matthew Porteus M.D., Ph.D. | Scientific Founder & Advisory Board Member | 1965 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...